DocMorris LtdSIX: DOCM

DOCM: Strong Rx and TeleClinic growth, fully underwritten CHF 200m raise, EBITDA break-even in 2026

· Issued by DocMorris Ltd

Q1 2025 saw 13% revenue growth, with Rx up 52% and TeleClinic revenue more than doubling. A CHF 200 million capital raise is fully underwritten to fund growth, with EBITDA break-even targeted in 2026 and positive free cash flow in 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

DocMorris Ltd on 6ix

Story so far

Earlier from DocMorris

Later from DocMorris

All DocMorris news releases